NCT05697588 · RECRUITING
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
This is an observational study, not a treatment trial. Researchers in China are following people with mild cognitive impairment over five years to find biological markers — from brain scans, electrical brain activity, blood tests, and cognitive assessments — that predict who will progress to dementia. There is no drug or intervention being tested. It is a data-gathering study aimed at building better prediction models for future use.
Eligibility criteria
Inclusion Criteria:
* Male or female patients aged ≥50 and ≤85 years;
* Meet the diagnostic criteria for dementia or MCI; ③ Neuropsychological score: MMSE 15-28 points, CDR≤1 point; ④ The patients and their families were informed and signed the informed consent.
Exclusion Criteria:
* There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.);
* There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);
* Suffering from a disease that cannot cooperate with the completion of cognitive examination; ④ There are contraindications to nuclear magnetic resonance;
* There is mental and neurodevelopmental delay; ⑥ refuse to draw blood; ⑦ Refuse to sign the informed consent.The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-07-24